Tesamorelin: GHRH Analog Research Guide

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH) that has been chemically modified to resist enzymatic degradation. The molecule features a trans-3-hexenoyl group attached to the N-terminal tyrosine residue, which: - Dramatically extends half-life compared to native GHRH - Improves resistance to dipeptidyl peptidase-4 (DPP4) - Maintains GHRH receptor binding affinity - Binds to GHRH receptors in the pituitary gland - Stimulates physiological (pulsatile) GH release - Increases IGF-1 production downstream - Preserves natural feedback mechanisms Studies have examined Tesamorelin in: - Lipodystrophy models (visceral fat reduction) - Metabolic syndrome research - Growth hormone axis investigation - Body composition studies - Visceral adipose tissue: Significant reduction observed - Metabolic parameters: Improved triglycerides and cholesterol ratios - Glucose tolerance: No adverse effects in studies - Muscle quality: Increased density and area Studies in hepatic fat models show: - Reduction in liver fat content - Improved liver enzyme markers - Prevention of inflammation and fibrosis progression | Feature | Tesamorelin (GHRH analog) | Recombinant GH | |---------|--------------------------|----------------| | GH Secretion | Physiological pulsatile | Supraphysiologic constant | | IGF-1 Feedback | Preserved | Overridden | | Insulin Resistance | Minimal/none | Common concern | | Fluid Retention | Rare | More common | Research has identified factors associated with better outcomes: - Metabolic syndrome markers - Elevated baseline triglycerides - Specific demographic factors - Effects require continuous administration - Benefits are transient and reverse upon discontinuation - Well-tolerated with predictable side effect profile - Injection site reactions most common - Store lyophilized at 2-8°C - Reconstitute with sterile water - Use within recommended timeframe after reconstitution Note: This compound is for research purposes only.